Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Синдром раздраженного кишечника: актуальные аспекты этиологии, патогенеза, клиники и лечения
Синдром раздраженного кишечника: актуальные аспекты этиологии, патогенеза, клиники и лечения
Трухан Д.И., Голошубина В.В. Синдром раздраженного кишечника: актуальные аспекты этиологии, патогенеза, клиники и лечения. Consilium Medicum. 2022;24(5):297–305.
DOI: 10.26442/20751753.2022.5.201861
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
DOI: 10.26442/20751753.2022.5.201861
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Среди функциональных гастроинтестинальных расстройств синдром раздраженного кишечника (СРК) по праву продолжает сохранять ведущие позиции. СРК является своеобразным эталоном для понимания патогенетической сути функциональных заболеваний органов пищеварения, поскольку это наиболее распространенная, изученная и изучаемая патология. Так, по запросу «Irritable Bowel Syndrome» в электронной базе PubMed на 30.07.2022 найдено 16 599 источников, а по запросу «синдром раздраженного кишечника» в научной электронной библиотеке eLIBRARY.RU – 6316. В первой части обзора рассматриваются актуальные аспекты этиологии, патогенеза и клиники СРК. Актуальность проблемы СРК связана со значительным снижением качества жизни пациентов. В обзоре сделан акцент на роли психоэмоциональных расстройств, изменений, локализованных на уровне кишечной стенки, а также на роли COVID-19 в развитии СРК. Абдоминальная боль как ведущее проявление СРК связана в первую очередь со спазмом. В этом контексте спазмолитические препараты можно рассматривать не только как симптоматические, но и как средства патогенетической терапии СРК. Во второй части обзора подробно рассмотрены возможности одного из миотропных спазмолитиков в лечении СРК – мебеверина гидрохлорида.
Ключевые слова: синдром раздраженного кишечника, этиология, патогенез, качество жизни, психоэмоциональные расстройства, синдром повышенной эпителиальной проницаемости, клиника, абдоминальная боль, лечение, спазмолитики, мебеверин
Keywords: irritable bowel syndrome, etiology, pathogenesis, quality of life, psychoemotional disorders, increased epithelial permeability syndrome, clinic, abdominal pain, treatment, antispasmodics, mebeverine
Ключевые слова: синдром раздраженного кишечника, этиология, патогенез, качество жизни, психоэмоциональные расстройства, синдром повышенной эпителиальной проницаемости, клиника, абдоминальная боль, лечение, спазмолитики, мебеверин
________________________________________________
Keywords: irritable bowel syndrome, etiology, pathogenesis, quality of life, psychoemotional disorders, increased epithelial permeability syndrome, clinic, abdominal pain, treatment, antispasmodics, mebeverine
Полный текст
Список литературы
1. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95 [Ivashkin VT, Maev IV, Shelygin YuA. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95 (in Russian)]. DOI:10.22416/1382-4376-2021-31-5-74-95
2. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1257-61. DOI:10.1053/j.gastro.2016.03.035
3. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. DOI:010.5056/jnm16214
4. Ивашкин В.Т. Методические рекомендации по лечению синдрома раздраженного кишечника (СРК). Режим доступа: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Ссылка активна на 22.08.2022 [Ivashkin VT. Metodicheskie rekomendatsii po lecheniiu sindroma razdrazhennogo kishechnika (SRK). Available at: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Accessed: 22.08.2022 (in Russian)].
5. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16):00222-5. DOI:10.1053/j.gastro.2016.02.031
6. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение: учеб. пособие. СПб: СпецЛит, 2013. Режим доступа: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Ссылка активна на 22.08.2022 [Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. Saint Petersburg: SpetsLit, 2013. Available at: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Accessed: 22.08.2022 (in Russian)].
7. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение: учеб. пособие. 2-е изд., испр. и доп. СПб: СпецЛит, 2022 [Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. 2-e izd., ispr. i dop. Saint Petersburg: SpetsLit, 2022 (in Russian)].
8. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001;19(6):643-53. DOI:10.2165/00019053-200119060-00003
9. Adam B, Liebregts T, Holtmann G. Irritable bowel syndrome. Dtsch Med Wochenschr. 2005;130(8):399-401. DOI:10.1055/s-2005-863064
10. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2012;24(6):702-7. DOI:10.1097/MEG.0b013e328351b2c2
11. Banerjee A, Sarkhel S, Sarkar R, Dhali GK. Anxiety and Depression in Irritable Bowel Syndrome. Indian J Psychol Med. 2017;39(6):741-5. DOI:10.4103/IJPSYM.IJPSYM_46_17
12. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
13. Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. DOI:10.26355/eurrev_201904_17580
14. Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450-60. DOI:10.3748/wjg.v22.i47.10450
15. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина. 2016 [Trukhan DI, Filimonov SN. Differentsial'nyi diagnoz osnovnykh gastroenterologicheskikh sindromov i simptomov. Moscow: Prakticheskaia meditsina. 2016 (in Russian)].
16. Cassar GE, Youssef GJ, Knowles S, et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020;43(3):E102-22. DOI:10.1097/SGA.0000000000000530
17. Chen J, Barandouzi ZA, Lee J, et al. Psychosocial and Sensory Factors Contribute to Self-Reported Pain and Quality of Life in Young Adults with Irritable Bowel Syndrome. Pain Manag Nurs. 2022:S1524-9042(21):00264-2. DOI:10.1016/j.pmn.2021.12.004
18. Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022. DOI:10.1002/ueg2.12277
19. Ромасенко Л.В., Махов В.М., Доронина Ю.А., Пархоменко И.М. Психосоматические соотношения у пациентов с дивертикулярной болезнью и синдромом раздраженного кишечника. Доктор.Ру. 2020;19(4):55-60 [Romasenko LV, Makhov VM, Doronina IuA, Parkhomenko IM. Psikhosomaticheskie sootnosheniia u patsientov s divertikuliarnoi bolezn'iu i sindromom razdrazhennogo kishechnika. Doktor.Ru. 2020;19(4):55-60 (in Russian)]. DOI:10.31550/1727-2378-2020-19-4-55-60
20. Тихонова Т.А., Козлова И.В. Синдром раздраженного кишечника: внекишечная коморбидность, психологические, морфометрические и генетические предикторы вариантов течения болезни. Экспериментальная и клиническая гастроэнтерология. 2022;3(199):5-14 [Tikhonova TA, Kozlova IV. Irritable bowel syndrome: extra-intestinal comorbidity, psychological, morphometric and genetic predictors of variants of the course of the disease. Surgical gastroenterology. 2022;3(199):5-14 (in Russian)].
DOI:10.31146/1682-8658-ecg-199-3-5-14
21. Трухан Д.И. На приеме пациентка с синдромом раздраженного кишечника. Медицинский совет. 2016;17:95-9 [Trukhan DI. A patient with irritable bowel syndrome at the doctor’s office. Meditsinskiy sovet=Medical Council. 2016;17:95-9 (in Russian)]. DOI:10.21518/2079-701X-2016-17-95-99
22. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
23. Khan EH, Ahamed F, Karim MR, et al. Psychiatric Morbidity in Irritable Bowel Syndrome. Mymensingh Med J. 2022;31(2):458-65.
24. Schwille-Kiuntke J, Ittermann T, Schmidt CO, et al. Quality of life and sleep in individuals with irritable bowel syndrome according to different diagnostic criteria and inflammatory bowel diseases: A comparison using data from a population-based survey. Z Gastroenterol. 2022;60(3):299-309. DOI:10.1055/a-1708-0277
25. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. DOI:10.1016/j.jpsychores.2022.110809
26. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 Suppl:S98-101. DOI:10.1097/MCG.0b013e31821fbf44
27. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
28. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744-52. DOI:10.1136/gutjnl-2012-304066
29. Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296-302. DOI:10.1111/nmo.12315
30. Hanning N, Edwinson AL, Ceuleers H, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI:10.1177/1756284821993586
31. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva N, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. DOI:10.15829/1728-8800-2021-2758
32. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022;94(8):6-22 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):6-22 (in Russian)]. DOI:10.26442/00403660.2022.08.201523
33. Голованова Е.В. Возможности коррекции функциональных расстройств желудочно-кишечного тракта у пациентов с тревожными расстройствами. РМЖ. 2020;6:45-8 [Golovanova EV. Treatment modalities for functional gastrointestinal disorders in patients with anxiety disorders. RMJ. 2020;6:45-8 (in Russian)].
34. Shigemura J, Ursano RJ, Morganstein JC, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281-2. DOI:10.1111/pcn.12988
35. Шадчнева Н.А., Тончева К.С., Геращенко Э.Ф. Синдром раздраженного кишечника, сочетанный с новой коронавирусной инфекцией. Modern Science. 2022;3-2:261-4 [Shadchneva NA, Toncheva KS, Gerashchenko EF. Sindrom razdrazhennogo kishechnika, sochetannyi s novoi koronavirusnoi infektsiei. Modern Science. 2022;3-2:261-4 (in Russian)].
36. Marturano M, Campagna G, Gaetani E, et al. 500 effects of COVID-19 pandemics on symptoms and quality of life in patients affected by interstitial cystitis/painful bladder syndrome (IC/PBS) and irritable bowel syndrome (IBS). Continence (Amst). 2022;2:1-2. DOI:10.1016/j.cont.2022.100451
37. Налетов А.В., Каспир Д.В., Курышева О.А. Патогенетические основы постковидного синдрома раздраженного кишечника (обзор литературы). Вестник неотложной и восстановительной хирургии. 2021;4(6):114-20 [Naletov AV, Kaspir DV, Kurysheva OA. Patogeneticheskie osnovy postkovidnogo sindroma razdrazhennogo kishechnika (obzor literatury). Vestnik neotlozhnoi i vosstanovitel'noi khirurgii. 2021;4(6):114-20 (in Russian)].
38. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. DOI:10.1038/s41586-021-03553-9
39. Sher L. Post-COVID syndrome and suicide risk. QJM. 2021;114(2):95-8. DOI:10.1093/qjmed/hcab007
40. Гриневич В.Б., Кравчук Ю.А. Болезни органов пищеварения и COVID-19. Известия Российской Военно-медицинской академии. 2021;40(3):39-44 [Grinevich VB, Kravchuk YA. Diseases of the digestive organs and COVID-19. Russian Military Medical Academy Reports. 2021;40(3):39-44 (in Russian)]. DOI:10.17816/rmmar76269
41. Маев И.В., Бордин Д.С., Ерёмина Е.Ю., и др. Cиндром раздраженного кишечника. Современные аспекты эпидемиологии, патогенеза и лечения (обзор). Экспериментальная и клиническая гастроэнтерология. 2018;158(10):68-73 [Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;(10):68-73 (in Russian)]. DOI:10.31146/1682-8658-ecg-158-10-68-73
42. Васильев Ю.В. Синдром раздраженного кишечника: современные аспекты диагностики и терапии. Медицинский совет. 2014;4:72-7 [Vasilyev YV. Irritable bowel syndrome: modern aspects of diagnosis and treatment. Meditsinskiy sovet=Medical Council. 2014;4:72-7 (in Russian)]. DOI:10.21518/2079-701X-2014-4-72-77
43. Карева Е.Н. Фармакология спазмолитических средств, применяемых в терапии синдрома раздраженного кишечника. Доктор.Ру. 2021;20(4):46-54 [Kareva EN. Farmakologiia spazmoliticheskikh sredstv, primeniaemykh v terapii sindroma razdrazhennogo kishechnika. Doktor.Ru. 2021;20(4):46-54 (in Russian)].
DOI:10.31550/1727-2378-2021-20-4-46-54
44. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. DOI:10.1046/j.1365-2036.2001.00937.x
45. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. DOI:10.1002/14651858.CD003460.pub3
46. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82-90. DOI:10.1016/j.rgmx.2012.04.002
47. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43. DOI:10.3748/wjg.v20.i20.6031
48. Маев И.В., Трухманов А.С., Шептулин А.А., и др. Роль нарушений моторики в патогенезе функциональных расстройств желудочно-кишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):7-14 [Maev IV, Trukhmanov AS, Sheptulin AA, et al. The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7-14 (in Russian)].
DOI:10.22416/1382-4376-2019-29-6-7-14
49. Лазебник Л.Б., Голованова Е.В., Волель Б.А., и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского Научного Медицинского Общества Терапевтов и Научного Общества Гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;192(8):5-117 [Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;192(8):5-117 (in Russian)]. DOI:10.31146/1682-8658-ecg-192-8-5-117
50. Agréus L, Svärdsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96(10):2905-14. DOI:10.1111/j.1572-0241.2001.04680.x
51. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
52. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:936960. DOI:10.1155/2012/936960
53. Маев И.В., Бордин Д.С., Ерёмина Е.Ю., и др. Cиндром раздраженного кишечника. Современные аспекты эпидемиологии, патогенеза и лечения (обзор). Экспериментальная и клиническая гастроэнтерология. 2018;158(10): 68-73 [Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;158(10):68-73 (in Russian)]. DOI:10.31146/1682-8658-ecg-158-10-68-73
54. Greenslade FC, Scott CK, Newquist KL, et al. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94-100. DOI:10.1002/jps.2600710123
55. Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions. Gut. 1993;34(6):799-802. DOI:10.1136/gut.34.6.799
56. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787-93.
DOI:10.1046/j.1365-2036.1996.61203000.x
57. Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5
DOI:10.1016/0014-2999(87)90594-2
58. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
59. Яковенко Э.П., Агафонова Н.А., Яковенко А.В., и др. Роль моторных нарушений в механизмах формирования клинических проявлений синдрома раздраженного кишечника (СРК) и СРК-подобных нарушений. Вопросы терапии. Consilium medicum. 2011;1:69-73 [Iakovenko EP, Agafonova NA, Iakovenko AV, et al. Rol' motornykh narushenii v mekhanizmakh formirovaniia klinicheskikh proiavlenii sindroma razdrazhennogo kishechnika (SRK) i SRK-podobnykh narushenii. Voprosy terapii. Consilium medicum. 2011;1:69-73 (in Russian)].
60. Lindner A, Selzer H, Claassen V, et al. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.
61. Макарчук П.А., Халиф И.Л., Михайлова Т.Л., Головенко О.В. Динамика показателей висцеральной чувствительности у больных с синдромом раздраженного кишечника при лечении спазмолитиками. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002;18(1):45-51 [Makarchuk PA, Khalif IL, Mikhaylova TL, Golovenko OV. Changes of visceral sensitivity in patients with irritable bowel syndrome at antispasmodics treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;18(1):45-51 (in Russian)].
62. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. DOI:10.3390/jcm11041044
63. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098-104. DOI:10.1111/j.1365-2982.2011.01771.x
64. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
65. Дроздов В.Н., Арефьев К.И., Максилак С.Ю., и др. Место спазмолитиков в лечении синдрома раздраженного кишечника. Медицинский совет. 2021;(5):155-64 [Drozdov VN, Arefev KI, Serebrova SYu, et al. Role of antispasmodics in the treatment of irritable bowel syndrome. Meditsinskiy sovet=Medical Council. 2021;(5):155-64 (in Russian)]. DOI:10.21518/2079- 701X-2021-5-155-164
66. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002;29(1-2):335-40. DOI:10.1016/s0731-7085(02)00023-7
67. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8(5):499-510. DOI:10.1111/j.1365-2036.1994.tb00322.x
68. Boisson J, Coudert P, Dupuis J, et al. Tolérance de la mébévérine à long terme. Act Ther. 1987;16(4):289-92.
69. Iwase M, Nishimura Y, Kurata N, et al. Inhibitory Effects of Gastrointestinal Drugs on CYP Activities in Human Liver Microsomes. Biol Pharm Bull. 2017;40(10):1654-60. DOI:10.1248/bpb.b17-00118
70. Schiariti M, Saladini A, Placanica A, et al. QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. Open Pharmacol J. 2009;3:32-6. DOI:10.2174/1874143600903010032
71. Müller-Lissner SA, Kaatz V, Brandt W, et al. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroenterol Hepatol. 2005;17(1):109-12. DOI:10.1097/00042737-200501000-00020
72. Dumitrascu DL, Chira A, Bataga S, et al. Romanian Society of Neurogastroenterology. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J Gastrointestin Liver Dis. 2014;23(4):431-5. DOI:10.15403/jgld.2014.1121.234.mibs
73. Полунина Т.Е. Синдром раздраженного кишечника и патология билиарного тракта. Клинический разбор. Медицинский Совет. 2020;(15):28-38 [Polunina TE. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Meditsinskiy sovet=Medical Council. 2020;(15):28-38 (in Russian)]. DOI:10.21518/2079-701X-2020-15-28-38
74. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2(5466):848-51. DOI:10.1136/bmj.2.5466.848
75. Трухан Д.И. Оригиналы и генерики: перезагрузка в свете экономического кризиса. Справочник поликлинического врача. 2012;4:32-6 [Trukhan DI. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Spravochnik poliklinicheskogo vracha. 2012;4:32-6 (in Russian)].
76. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012;10:18-24 [Trukhan DI. Ratsional'naia farmakoterapiia v gastroenterologii. Spravochnik poliklinicheskogo vracha. 2012;10:18-24 (in Russian)].
77. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;4:81-7 [Tarasova LV, Trukhan DI. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2013;4:81-7 (in Russian)].
78. Трухан Д.И., Тарасова Л.В. Лекарственная безопасность и рациональная фармакотерапия в гастроэнтерологической практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;5:9-16 [Trukhan DI, Tarasova LV. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klinicheskie perspektivy gastroenterologii, gepatologii. 2013;5:9-16 (in Russian)].
79. Беккер Р.А., Быков Ю.В. Эглонил®: замечательное триединство – атипичный антипсихотик, психосоматический препарат и антидепрессант. К 50-летию создания препарата. Психиатрия и психофармакотерапия. 2019;21(6):32-40 [Bekker RA, Bykov YuV. Eglonil®: a wonderful trinity – an atypical antipsychotic, a psychosomatic drug and an antidepressant. To the 50th anniversary of the start of its clinical use. Psychiatry and Psychopharmacotherapy. 2019;21(6):32-40 (in Russian)].
2. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1257-61. DOI:10.1053/j.gastro.2016.03.035
3. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. DOI:010.5056/jnm16214
4. Ivashkin VT. Metodicheskie rekomendatsii po lecheniiu sindroma razdrazhennogo kishechnika (SRK). Available at: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Accessed: 22.08.2022 (in Russian).
5. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16):00222-5. DOI:10.1053/j.gastro.2016.02.031
6. Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. Saint Petersburg: SpetsLit, 2013. Available at: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Accessed: 22.08.2022 (in Russian).
7. Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. 2-e izd., ispr. i dop. Saint Petersburg: SpetsLit, 2022 (in Russian).
8. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001;19(6):643-53. DOI:10.2165/00019053-200119060-00003
9. Adam B, Liebregts T, Holtmann G. Irritable bowel syndrome. Dtsch Med Wochenschr. 2005;130(8):399-401. DOI:10.1055/s-2005-863064
10. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2012;24(6):702-7. DOI:10.1097/MEG.0b013e328351b2c2
11. Banerjee A, Sarkhel S, Sarkar R, Dhali GK. Anxiety and Depression in Irritable Bowel Syndrome. Indian J Psychol Med. 2017;39(6):741-5. DOI:10.4103/IJPSYM.IJPSYM_46_17
12. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
13. Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. DOI:10.26355/eurrev_201904_17580
14. Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450-60. DOI:10.3748/wjg.v22.i47.10450
15. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина. 2016 [Trukhan DI, Filimonov SN. Differentsial'nyi diagnoz osnovnykh gastroenterologicheskikh sindromov i simptomov. Moscow: Prakticheskaia meditsina. 2016 (in Russian)].
16. Cassar GE, Youssef GJ, Knowles S, et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020;43(3):E102-22. DOI:10.1097/SGA.0000000000000530
17. Chen J, Barandouzi ZA, Lee J, et al. Psychosocial and Sensory Factors Contribute to Self-Reported Pain and Quality of Life in Young Adults with Irritable Bowel Syndrome. Pain Manag Nurs. 2022:S1524-9042(21):00264-2. DOI:10.1016/j.pmn.2021.12.004
18. Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022. DOI:10.1002/ueg2.12277
19. Romasenko LV, Makhov VM, Doronina IuA, Parkhomenko IM. Psikhosomaticheskie sootnosheniia u patsientov s divertikuliarnoi bolezn'iu i sindromom razdrazhennogo kishechnika. Doktor.Ru. 2020;19(4):55-60 (in Russian). DOI:10.31550/1727-2378-2020-19-4-55-60
20. Tikhonova TA, Kozlova IV. Irritable bowel syndrome: extra-intestinal comorbidity, psychological, morphometric and genetic predictors of variants of the course of the disease. Surgical gastroenterology. 2022;3(199):5-14 (in Russian). DOI:10.31146/1682-8658-ecg-199-3-5-14
21. Trukhan DI. A patient with irritable bowel syndrome at the doctor’s office. Meditsinskiy sovet=Medical Council. 2016;17:95-9 (in Russian). DOI:10.21518/2079-701X-2016-17-95-99
22. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
23. Khan EH, Ahamed F, Karim MR, et al. Psychiatric Morbidity in Irritable Bowel Syndrome. Mymensingh Med J. 2022;31(2):458-65.
24. Schwille-Kiuntke J, Ittermann T, Schmidt CO, et al. Quality of life and sleep in individuals with irritable bowel syndrome according to different diagnostic criteria and inflammatory bowel diseases: A comparison using data from a population-based survey. Z Gastroenterol. 2022;60(3):299-309. DOI:10.1055/a-1708-0277
25. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. DOI:10.1016/j.jpsychores.2022.110809
26. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 Suppl:S98-101. DOI:10.1097/MCG.0b013e31821fbf44
27. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
28. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744-52. DOI:10.1136/gutjnl-2012-304066
29. Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296-302. DOI:10.1111/nmo.12315
30. Hanning N, Edwinson AL, Ceuleers H, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI:10.1177/1756284821993586
31. Simanenkov VI, Maev IV, Tkacheva N, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian). DOI:10.15829/1728-8800-2021-2758
32. Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):6-22 (in Russian). DOI:10.26442/00403660.2022.08.201523
33. Golovanova EV. Treatment modalities for functional gastrointestinal disorders in patients with anxiety disorders. RMJ. 2020;6:45-8 (in Russian).
34. Shigemura J, Ursano RJ, Morganstein JC, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281-2. DOI:10.1111/pcn.12988
35. Shadchneva NA, Toncheva KS, Gerashchenko EF. Sindrom razdrazhennogo kishechnika, sochetannyi s novoi koronavirusnoi infektsiei. Modern Science. 2022;3-2:261-4 (in Russian).
36. Marturano M, Campagna G, Gaetani E, et al. 500 effects of COVID-19 pandemics on symptoms and quality of life in patients affected by interstitial cystitis/painful bladder syndrome (IC/PBS) and irritable bowel syndrome (IBS). Continence (Amst). 2022;2:1-2. DOI:10.1016/j.cont.2022.100451
37. Naletov AV, Kaspir DV, Kurysheva OA. Patogeneticheskie osnovy postkovidnogo sindroma razdrazhennogo kishechnika (obzor literatury). Vestnik neotlozhnoi i vosstanovitel'noi khirurgii. 2021;4(6):114-20 (in Russian).
38. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. DOI:10.1038/s41586-021-03553-9
39. Sher L. Post-COVID syndrome and suicide risk. QJM. 2021;114(2):95-8. DOI:10.1093/qjmed/hcab007
40. Grinevich VB, Kravchuk YA. Diseases of the digestive organs and COVID-19. Russian Military Medical Academy Reports. 2021;40(3):39-44 (in Russian). DOI:10.17816/rmmar76269
41. Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;(10):68-73 (in Russian). DOI:10.31146/1682-8658-ecg-158-10-68-73
42. Vasilyev YV. Irritable bowel syndrome: modern aspects of diagnosis and treatment. Meditsinskiy sovet=Medical Council. 2014;4:72-7 (in Russian).
DOI:10.21518/2079-701X-2014-4-72-77
43. Kareva EN. Farmakologiia spazmoliticheskikh sredstv, primeniaemykh v terapii sindroma razdrazhennogo kishechnika. Doktor.Ru. 2021;20(4):46-54 (in Russian).
DOI:10.31550/1727-2378-2021-20-4-46-54
44. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. DOI:10.1046/j.1365-2036.2001.00937.x
45. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. DOI:10.1002/14651858.CD003460.pub3
46. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82-90. DOI:10.1016/j.rgmx.2012.04.002
47. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43. DOI:10.3748/wjg.v20.i20.6031
48. Maev IV, Trukhmanov AS, Sheptulin AA, et al. The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7-14 (in Russian).
DOI:10.22416/1382-4376-2019-29-6-7-14
49. Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;192(8):5-117 (in Russian). DOI:10.31146/1682-8658-ecg-192-8-5-117
50. Agréus L, Svärdsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96(10):2905-14. DOI:10.1111/j.1572-0241.2001.04680.x
51. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
52. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:936960. DOI:10.1155/2012/936960
53. Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;158(10):68-73 (in Russian). DOI:10.31146/1682-8658-ecg-158-10-68-73
54. Greenslade FC, Scott CK, Newquist KL, et al. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94-100. DOI:10.1002/jps.2600710123
55. Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions. Gut. 1993;34(6):799-802. DOI:10.1136/gut.34.6.799
56. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787-93.
DOI:10.1046/j.1365-2036.1996.61203000.x
57. Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5
DOI:10.1016/0014-2999(87)90594-2
58. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
59. Iakovenko EP, Agafonova NA, Iakovenko AV, et al. Rol' motornykh narushenii v mekhanizmakh formirovaniia klinicheskikh proiavlenii sindroma razdrazhennogo kishechnika (SRK) i SRK-podobnykh narushenii. Voprosy terapii. Consilium medicum. 2011;1:69-73 (in Russian).
60. Lindner A, Selzer H, Claassen V, et al. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.
61. Makarchuk PA, Khalif IL, Mikhaylova TL, Golovenko OV. Changes of visceral sensitivity in patients with irritable bowel syndrome at antispasmodics treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;18(1):45-51 (in Russian).
62. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. DOI:10.3390/jcm11041044
63. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098-104. DOI:10.1111/j.1365-2982.2011.01771.x
64. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
65. Drozdov VN, Arefev KI, Serebrova SYu, et al. Role of antispasmodics in the treatment of irritable bowel syndrome. Meditsinskiy sovet=Medical Council. 2021;(5):155-64 (in Russian). DOI:10.21518/2079- 701X-2021-5-155-164
66. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002;29(1-2):335-40. DOI:10.1016/s0731-7085(02)00023-7
67. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8(5):499-510. DOI:10.1111/j.1365-2036.1994.tb00322.x
68. Boisson J, Coudert P, Dupuis J, et al. Tolérance de la mébévérine à long terme. Act Ther. 1987;16(4):289-92.
69. Iwase M, Nishimura Y, Kurata N, et al. Inhibitory Effects of Gastrointestinal Drugs on CYP Activities in Human Liver Microsomes. Biol Pharm Bull. 2017;40(10):1654-60. DOI:10.1248/bpb.b17-00118
70. Schiariti M, Saladini A, Placanica A, et al. QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. Open Pharmacol J. 2009;3:32-6. DOI:10.2174/1874143600903010032
71. Müller-Lissner SA, Kaatz V, Brandt W, et al. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroenterol Hepatol. 2005;17(1):109-12. DOI:10.1097/00042737-200501000-00020
72. Dumitrascu DL, Chira A, Bataga S, et al. Romanian Society of Neurogastroenterology. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J Gastrointestin Liver Dis. 2014;23(4):431-5. DOI:10.15403/jgld.2014.1121.234.mibs
73. Polunina TE. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Meditsinskiy sovet=Medical Council. 2020;(15):28-38 (in Russian).
DOI:10.21518/2079-701X-2020-15-28-38
74. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2(5466):848-51. DOI:10.1136/bmj.2.5466.848
75. Trukhan DI. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Spravochnik poliklinicheskogo vracha. 2012;4:32-6 (in Russian).
76. Trukhan DI. Ratsional'naia farmakoterapiia v gastroenterologii. Spravochnik poliklinicheskogo vracha. 2012;10:18-24 (in Russian).
77. Tarasova LV, Trukhan DI. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2013;4:81-7 (in Russian).
78. Trukhan DI, Tarasova LV. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klinicheskie perspektivy gastroenterologii, gepatologii. 2013;5:9-16 (in Russian).
79. Bekker RA, Bykov YuV. Eglonil®: a wonderful trinity – an atypical antipsychotic, a psychosomatic drug and an antidepressant. To the 50th anniversary of the start of its clinical use. Psychiatry and Psychopharmacotherapy. 2019;21(6):32-40 (in Russian).
2. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1257-61. DOI:10.1053/j.gastro.2016.03.035
3. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. DOI:010.5056/jnm16214
4. Ивашкин В.Т. Методические рекомендации по лечению синдрома раздраженного кишечника (СРК). Режим доступа: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Ссылка активна на 22.08.2022 [Ivashkin VT. Metodicheskie rekomendatsii po lecheniiu sindroma razdrazhennogo kishechnika (SRK). Available at: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Accessed: 22.08.2022 (in Russian)].
5. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16):00222-5. DOI:10.1053/j.gastro.2016.02.031
6. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение: учеб. пособие. СПб: СпецЛит, 2013. Режим доступа: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Ссылка активна на 22.08.2022 [Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. Saint Petersburg: SpetsLit, 2013. Available at: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Accessed: 22.08.2022 (in Russian)].
7. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение: учеб. пособие. 2-е изд., испр. и доп. СПб: СпецЛит, 2022 [Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. 2-e izd., ispr. i dop. Saint Petersburg: SpetsLit, 2022 (in Russian)].
8. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001;19(6):643-53. DOI:10.2165/00019053-200119060-00003
9. Adam B, Liebregts T, Holtmann G. Irritable bowel syndrome. Dtsch Med Wochenschr. 2005;130(8):399-401. DOI:10.1055/s-2005-863064
10. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2012;24(6):702-7. DOI:10.1097/MEG.0b013e328351b2c2
11. Banerjee A, Sarkhel S, Sarkar R, Dhali GK. Anxiety and Depression in Irritable Bowel Syndrome. Indian J Psychol Med. 2017;39(6):741-5. DOI:10.4103/IJPSYM.IJPSYM_46_17
12. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
13. Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. DOI:10.26355/eurrev_201904_17580
14. Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450-60. DOI:10.3748/wjg.v22.i47.10450
15. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина. 2016 [Trukhan DI, Filimonov SN. Differentsial'nyi diagnoz osnovnykh gastroenterologicheskikh sindromov i simptomov. Moscow: Prakticheskaia meditsina. 2016 (in Russian)].
16. Cassar GE, Youssef GJ, Knowles S, et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020;43(3):E102-22. DOI:10.1097/SGA.0000000000000530
17. Chen J, Barandouzi ZA, Lee J, et al. Psychosocial and Sensory Factors Contribute to Self-Reported Pain and Quality of Life in Young Adults with Irritable Bowel Syndrome. Pain Manag Nurs. 2022:S1524-9042(21):00264-2. DOI:10.1016/j.pmn.2021.12.004
18. Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022. DOI:10.1002/ueg2.12277
19. Ромасенко Л.В., Махов В.М., Доронина Ю.А., Пархоменко И.М. Психосоматические соотношения у пациентов с дивертикулярной болезнью и синдромом раздраженного кишечника. Доктор.Ру. 2020;19(4):55-60 [Romasenko LV, Makhov VM, Doronina IuA, Parkhomenko IM. Psikhosomaticheskie sootnosheniia u patsientov s divertikuliarnoi bolezn'iu i sindromom razdrazhennogo kishechnika. Doktor.Ru. 2020;19(4):55-60 (in Russian)]. DOI:10.31550/1727-2378-2020-19-4-55-60
20. Тихонова Т.А., Козлова И.В. Синдром раздраженного кишечника: внекишечная коморбидность, психологические, морфометрические и генетические предикторы вариантов течения болезни. Экспериментальная и клиническая гастроэнтерология. 2022;3(199):5-14 [Tikhonova TA, Kozlova IV. Irritable bowel syndrome: extra-intestinal comorbidity, psychological, morphometric and genetic predictors of variants of the course of the disease. Surgical gastroenterology. 2022;3(199):5-14 (in Russian)].
DOI:10.31146/1682-8658-ecg-199-3-5-14
21. Трухан Д.И. На приеме пациентка с синдромом раздраженного кишечника. Медицинский совет. 2016;17:95-9 [Trukhan DI. A patient with irritable bowel syndrome at the doctor’s office. Meditsinskiy sovet=Medical Council. 2016;17:95-9 (in Russian)]. DOI:10.21518/2079-701X-2016-17-95-99
22. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
23. Khan EH, Ahamed F, Karim MR, et al. Psychiatric Morbidity in Irritable Bowel Syndrome. Mymensingh Med J. 2022;31(2):458-65.
24. Schwille-Kiuntke J, Ittermann T, Schmidt CO, et al. Quality of life and sleep in individuals with irritable bowel syndrome according to different diagnostic criteria and inflammatory bowel diseases: A comparison using data from a population-based survey. Z Gastroenterol. 2022;60(3):299-309. DOI:10.1055/a-1708-0277
25. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. DOI:10.1016/j.jpsychores.2022.110809
26. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 Suppl:S98-101. DOI:10.1097/MCG.0b013e31821fbf44
27. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
28. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744-52. DOI:10.1136/gutjnl-2012-304066
29. Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296-302. DOI:10.1111/nmo.12315
30. Hanning N, Edwinson AL, Ceuleers H, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI:10.1177/1756284821993586
31. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758 [Simanenkov VI, Maev IV, Tkacheva N, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian)]. DOI:10.15829/1728-8800-2021-2758
32. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022;94(8):6-22 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):6-22 (in Russian)]. DOI:10.26442/00403660.2022.08.201523
33. Голованова Е.В. Возможности коррекции функциональных расстройств желудочно-кишечного тракта у пациентов с тревожными расстройствами. РМЖ. 2020;6:45-8 [Golovanova EV. Treatment modalities for functional gastrointestinal disorders in patients with anxiety disorders. RMJ. 2020;6:45-8 (in Russian)].
34. Shigemura J, Ursano RJ, Morganstein JC, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281-2. DOI:10.1111/pcn.12988
35. Шадчнева Н.А., Тончева К.С., Геращенко Э.Ф. Синдром раздраженного кишечника, сочетанный с новой коронавирусной инфекцией. Modern Science. 2022;3-2:261-4 [Shadchneva NA, Toncheva KS, Gerashchenko EF. Sindrom razdrazhennogo kishechnika, sochetannyi s novoi koronavirusnoi infektsiei. Modern Science. 2022;3-2:261-4 (in Russian)].
36. Marturano M, Campagna G, Gaetani E, et al. 500 effects of COVID-19 pandemics on symptoms and quality of life in patients affected by interstitial cystitis/painful bladder syndrome (IC/PBS) and irritable bowel syndrome (IBS). Continence (Amst). 2022;2:1-2. DOI:10.1016/j.cont.2022.100451
37. Налетов А.В., Каспир Д.В., Курышева О.А. Патогенетические основы постковидного синдрома раздраженного кишечника (обзор литературы). Вестник неотложной и восстановительной хирургии. 2021;4(6):114-20 [Naletov AV, Kaspir DV, Kurysheva OA. Patogeneticheskie osnovy postkovidnogo sindroma razdrazhennogo kishechnika (obzor literatury). Vestnik neotlozhnoi i vosstanovitel'noi khirurgii. 2021;4(6):114-20 (in Russian)].
38. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. DOI:10.1038/s41586-021-03553-9
39. Sher L. Post-COVID syndrome and suicide risk. QJM. 2021;114(2):95-8. DOI:10.1093/qjmed/hcab007
40. Гриневич В.Б., Кравчук Ю.А. Болезни органов пищеварения и COVID-19. Известия Российской Военно-медицинской академии. 2021;40(3):39-44 [Grinevich VB, Kravchuk YA. Diseases of the digestive organs and COVID-19. Russian Military Medical Academy Reports. 2021;40(3):39-44 (in Russian)]. DOI:10.17816/rmmar76269
41. Маев И.В., Бордин Д.С., Ерёмина Е.Ю., и др. Cиндром раздраженного кишечника. Современные аспекты эпидемиологии, патогенеза и лечения (обзор). Экспериментальная и клиническая гастроэнтерология. 2018;158(10):68-73 [Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;(10):68-73 (in Russian)]. DOI:10.31146/1682-8658-ecg-158-10-68-73
42. Васильев Ю.В. Синдром раздраженного кишечника: современные аспекты диагностики и терапии. Медицинский совет. 2014;4:72-7 [Vasilyev YV. Irritable bowel syndrome: modern aspects of diagnosis and treatment. Meditsinskiy sovet=Medical Council. 2014;4:72-7 (in Russian)]. DOI:10.21518/2079-701X-2014-4-72-77
43. Карева Е.Н. Фармакология спазмолитических средств, применяемых в терапии синдрома раздраженного кишечника. Доктор.Ру. 2021;20(4):46-54 [Kareva EN. Farmakologiia spazmoliticheskikh sredstv, primeniaemykh v terapii sindroma razdrazhennogo kishechnika. Doktor.Ru. 2021;20(4):46-54 (in Russian)].
DOI:10.31550/1727-2378-2021-20-4-46-54
44. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. DOI:10.1046/j.1365-2036.2001.00937.x
45. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. DOI:10.1002/14651858.CD003460.pub3
46. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82-90. DOI:10.1016/j.rgmx.2012.04.002
47. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43. DOI:10.3748/wjg.v20.i20.6031
48. Маев И.В., Трухманов А.С., Шептулин А.А., и др. Роль нарушений моторики в патогенезе функциональных расстройств желудочно-кишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):7-14 [Maev IV, Trukhmanov AS, Sheptulin AA, et al. The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7-14 (in Russian)].
DOI:10.22416/1382-4376-2019-29-6-7-14
49. Лазебник Л.Б., Голованова Е.В., Волель Б.А., и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского Научного Медицинского Общества Терапевтов и Научного Общества Гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;192(8):5-117 [Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;192(8):5-117 (in Russian)]. DOI:10.31146/1682-8658-ecg-192-8-5-117
50. Agréus L, Svärdsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96(10):2905-14. DOI:10.1111/j.1572-0241.2001.04680.x
51. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
52. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:936960. DOI:10.1155/2012/936960
53. Маев И.В., Бордин Д.С., Ерёмина Е.Ю., и др. Cиндром раздраженного кишечника. Современные аспекты эпидемиологии, патогенеза и лечения (обзор). Экспериментальная и клиническая гастроэнтерология. 2018;158(10): 68-73 [Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;158(10):68-73 (in Russian)]. DOI:10.31146/1682-8658-ecg-158-10-68-73
54. Greenslade FC, Scott CK, Newquist KL, et al. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94-100. DOI:10.1002/jps.2600710123
55. Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions. Gut. 1993;34(6):799-802. DOI:10.1136/gut.34.6.799
56. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787-93.
DOI:10.1046/j.1365-2036.1996.61203000.x
57. Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5
DOI:10.1016/0014-2999(87)90594-2
58. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
59. Яковенко Э.П., Агафонова Н.А., Яковенко А.В., и др. Роль моторных нарушений в механизмах формирования клинических проявлений синдрома раздраженного кишечника (СРК) и СРК-подобных нарушений. Вопросы терапии. Consilium medicum. 2011;1:69-73 [Iakovenko EP, Agafonova NA, Iakovenko AV, et al. Rol' motornykh narushenii v mekhanizmakh formirovaniia klinicheskikh proiavlenii sindroma razdrazhennogo kishechnika (SRK) i SRK-podobnykh narushenii. Voprosy terapii. Consilium medicum. 2011;1:69-73 (in Russian)].
60. Lindner A, Selzer H, Claassen V, et al. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.
61. Макарчук П.А., Халиф И.Л., Михайлова Т.Л., Головенко О.В. Динамика показателей висцеральной чувствительности у больных с синдромом раздраженного кишечника при лечении спазмолитиками. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002;18(1):45-51 [Makarchuk PA, Khalif IL, Mikhaylova TL, Golovenko OV. Changes of visceral sensitivity in patients with irritable bowel syndrome at antispasmodics treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;18(1):45-51 (in Russian)].
62. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. DOI:10.3390/jcm11041044
63. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098-104. DOI:10.1111/j.1365-2982.2011.01771.x
64. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
65. Дроздов В.Н., Арефьев К.И., Максилак С.Ю., и др. Место спазмолитиков в лечении синдрома раздраженного кишечника. Медицинский совет. 2021;(5):155-64 [Drozdov VN, Arefev KI, Serebrova SYu, et al. Role of antispasmodics in the treatment of irritable bowel syndrome. Meditsinskiy sovet=Medical Council. 2021;(5):155-64 (in Russian)]. DOI:10.21518/2079- 701X-2021-5-155-164
66. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002;29(1-2):335-40. DOI:10.1016/s0731-7085(02)00023-7
67. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8(5):499-510. DOI:10.1111/j.1365-2036.1994.tb00322.x
68. Boisson J, Coudert P, Dupuis J, et al. Tolérance de la mébévérine à long terme. Act Ther. 1987;16(4):289-92.
69. Iwase M, Nishimura Y, Kurata N, et al. Inhibitory Effects of Gastrointestinal Drugs on CYP Activities in Human Liver Microsomes. Biol Pharm Bull. 2017;40(10):1654-60. DOI:10.1248/bpb.b17-00118
70. Schiariti M, Saladini A, Placanica A, et al. QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. Open Pharmacol J. 2009;3:32-6. DOI:10.2174/1874143600903010032
71. Müller-Lissner SA, Kaatz V, Brandt W, et al. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroenterol Hepatol. 2005;17(1):109-12. DOI:10.1097/00042737-200501000-00020
72. Dumitrascu DL, Chira A, Bataga S, et al. Romanian Society of Neurogastroenterology. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J Gastrointestin Liver Dis. 2014;23(4):431-5. DOI:10.15403/jgld.2014.1121.234.mibs
73. Полунина Т.Е. Синдром раздраженного кишечника и патология билиарного тракта. Клинический разбор. Медицинский Совет. 2020;(15):28-38 [Polunina TE. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Meditsinskiy sovet=Medical Council. 2020;(15):28-38 (in Russian)]. DOI:10.21518/2079-701X-2020-15-28-38
74. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2(5466):848-51. DOI:10.1136/bmj.2.5466.848
75. Трухан Д.И. Оригиналы и генерики: перезагрузка в свете экономического кризиса. Справочник поликлинического врача. 2012;4:32-6 [Trukhan DI. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Spravochnik poliklinicheskogo vracha. 2012;4:32-6 (in Russian)].
76. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012;10:18-24 [Trukhan DI. Ratsional'naia farmakoterapiia v gastroenterologii. Spravochnik poliklinicheskogo vracha. 2012;10:18-24 (in Russian)].
77. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;4:81-7 [Tarasova LV, Trukhan DI. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2013;4:81-7 (in Russian)].
78. Трухан Д.И., Тарасова Л.В. Лекарственная безопасность и рациональная фармакотерапия в гастроэнтерологической практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;5:9-16 [Trukhan DI, Tarasova LV. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klinicheskie perspektivy gastroenterologii, gepatologii. 2013;5:9-16 (in Russian)].
79. Беккер Р.А., Быков Ю.В. Эглонил®: замечательное триединство – атипичный антипсихотик, психосоматический препарат и антидепрессант. К 50-летию создания препарата. Психиатрия и психофармакотерапия. 2019;21(6):32-40 [Bekker RA, Bykov YuV. Eglonil®: a wonderful trinity – an atypical antipsychotic, a psychosomatic drug and an antidepressant. To the 50th anniversary of the start of its clinical use. Psychiatry and Psychopharmacotherapy. 2019;21(6):32-40 (in Russian)].
________________________________________________
2. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1257-61. DOI:10.1053/j.gastro.2016.03.035
3. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. DOI:010.5056/jnm16214
4. Ivashkin VT. Metodicheskie rekomendatsii po lecheniiu sindroma razdrazhennogo kishechnika (SRK). Available at: https://internist.ru/publications/detail/metodicheskie-rekomendacii-po-lecheniyu-sindroma-razdrazhen... Accessed: 22.08.2022 (in Russian).
5. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16):00222-5. DOI:10.1053/j.gastro.2016.02.031
6. Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. Saint Petersburg: SpetsLit, 2013. Available at: https://speclit.su/image/catalog/978-5-299-00561-5/978-5-299-00561-5.pdf?ysclid=l69ps9mwr6430198359/ Accessed: 22.08.2022 (in Russian).
7. Tarasova LV, Trukhan DI. Bolezni kishechnika. Klinika, diagnostika i lechenie: ucheb. posobie. 2-e izd., ispr. i dop. Saint Petersburg: SpetsLit, 2022 (in Russian).
8. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001;19(6):643-53. DOI:10.2165/00019053-200119060-00003
9. Adam B, Liebregts T, Holtmann G. Irritable bowel syndrome. Dtsch Med Wochenschr. 2005;130(8):399-401. DOI:10.1055/s-2005-863064
10. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2012;24(6):702-7. DOI:10.1097/MEG.0b013e328351b2c2
11. Banerjee A, Sarkhel S, Sarkar R, Dhali GK. Anxiety and Depression in Irritable Bowel Syndrome. Indian J Psychol Med. 2017;39(6):741-5. DOI:10.4103/IJPSYM.IJPSYM_46_17
12. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
13. Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986-3000. DOI:10.26355/eurrev_201904_17580
14. Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450-60. DOI:10.3748/wjg.v22.i47.10450
15. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина. 2016 [Trukhan DI, Filimonov SN. Differentsial'nyi diagnoz osnovnykh gastroenterologicheskikh sindromov i simptomov. Moscow: Prakticheskaia meditsina. 2016 (in Russian)].
16. Cassar GE, Youssef GJ, Knowles S, et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020;43(3):E102-22. DOI:10.1097/SGA.0000000000000530
17. Chen J, Barandouzi ZA, Lee J, et al. Psychosocial and Sensory Factors Contribute to Self-Reported Pain and Quality of Life in Young Adults with Irritable Bowel Syndrome. Pain Manag Nurs. 2022:S1524-9042(21):00264-2. DOI:10.1016/j.pmn.2021.12.004
18. Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022. DOI:10.1002/ueg2.12277
19. Romasenko LV, Makhov VM, Doronina IuA, Parkhomenko IM. Psikhosomaticheskie sootnosheniia u patsientov s divertikuliarnoi bolezn'iu i sindromom razdrazhennogo kishechnika. Doktor.Ru. 2020;19(4):55-60 (in Russian). DOI:10.31550/1727-2378-2020-19-4-55-60
20. Tikhonova TA, Kozlova IV. Irritable bowel syndrome: extra-intestinal comorbidity, psychological, morphometric and genetic predictors of variants of the course of the disease. Surgical gastroenterology. 2022;3(199):5-14 (in Russian). DOI:10.31146/1682-8658-ecg-199-3-5-14
21. Trukhan DI. A patient with irritable bowel syndrome at the doctor’s office. Meditsinskiy sovet=Medical Council. 2016;17:95-9 (in Russian). DOI:10.21518/2079-701X-2016-17-95-99
22. Zhang QE, Wang F, Qin G, et al. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14(11):1504-12. DOI:10.7150/ijbs.25001
23. Khan EH, Ahamed F, Karim MR, et al. Psychiatric Morbidity in Irritable Bowel Syndrome. Mymensingh Med J. 2022;31(2):458-65.
24. Schwille-Kiuntke J, Ittermann T, Schmidt CO, et al. Quality of life and sleep in individuals with irritable bowel syndrome according to different diagnostic criteria and inflammatory bowel diseases: A comparison using data from a population-based survey. Z Gastroenterol. 2022;60(3):299-309. DOI:10.1055/a-1708-0277
25. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. DOI:10.1016/j.jpsychores.2022.110809
26. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 Suppl:S98-101. DOI:10.1097/MCG.0b013e31821fbf44
27. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. DOI:10.1152/ajpgi.00155.2012
28. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744-52. DOI:10.1136/gutjnl-2012-304066
29. Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296-302. DOI:10.1111/nmo.12315
30. Hanning N, Edwinson AL, Ceuleers H, et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI:10.1177/1756284821993586
31. Simanenkov VI, Maev IV, Tkacheva N, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758 (in Russian). DOI:10.15829/1728-8800-2021-2758
32. Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):6-22 (in Russian). DOI:10.26442/00403660.2022.08.201523
33. Golovanova EV. Treatment modalities for functional gastrointestinal disorders in patients with anxiety disorders. RMJ. 2020;6:45-8 (in Russian).
34. Shigemura J, Ursano RJ, Morganstein JC, et al. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281-2. DOI:10.1111/pcn.12988
35. Shadchneva NA, Toncheva KS, Gerashchenko EF. Sindrom razdrazhennogo kishechnika, sochetannyi s novoi koronavirusnoi infektsiei. Modern Science. 2022;3-2:261-4 (in Russian).
36. Marturano M, Campagna G, Gaetani E, et al. 500 effects of COVID-19 pandemics on symptoms and quality of life in patients affected by interstitial cystitis/painful bladder syndrome (IC/PBS) and irritable bowel syndrome (IBS). Continence (Amst). 2022;2:1-2. DOI:10.1016/j.cont.2022.100451
37. Naletov AV, Kaspir DV, Kurysheva OA. Patogeneticheskie osnovy postkovidnogo sindroma razdrazhennogo kishechnika (obzor literatury). Vestnik neotlozhnoi i vosstanovitel'noi khirurgii. 2021;4(6):114-20 (in Russian).
38. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. DOI:10.1038/s41586-021-03553-9
39. Sher L. Post-COVID syndrome and suicide risk. QJM. 2021;114(2):95-8. DOI:10.1093/qjmed/hcab007
40. Grinevich VB, Kravchuk YA. Diseases of the digestive organs and COVID-19. Russian Military Medical Academy Reports. 2021;40(3):39-44 (in Russian). DOI:10.17816/rmmar76269
41. Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;(10):68-73 (in Russian). DOI:10.31146/1682-8658-ecg-158-10-68-73
42. Vasilyev YV. Irritable bowel syndrome: modern aspects of diagnosis and treatment. Meditsinskiy sovet=Medical Council. 2014;4:72-7 (in Russian).
DOI:10.21518/2079-701X-2014-4-72-77
43. Kareva EN. Farmakologiia spazmoliticheskikh sredstv, primeniaemykh v terapii sindroma razdrazhennogo kishechnika. Doktor.Ru. 2021;20(4):46-54 (in Russian).
DOI:10.31550/1727-2378-2021-20-4-46-54
44. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. DOI:10.1046/j.1365-2036.2001.00937.x
45. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. DOI:10.1002/14651858.CD003460.pub3
46. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82-90. DOI:10.1016/j.rgmx.2012.04.002
47. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43. DOI:10.3748/wjg.v20.i20.6031
48. Maev IV, Trukhmanov AS, Sheptulin AA, et al. The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7-14 (in Russian).
DOI:10.22416/1382-4376-2019-29-6-7-14
49. Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;192(8):5-117 (in Russian). DOI:10.31146/1682-8658-ecg-192-8-5-117
50. Agréus L, Svärdsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96(10):2905-14. DOI:10.1111/j.1572-0241.2001.04680.x
51. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. DOI:10.1038/ajg.2008.122
52. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:936960. DOI:10.1155/2012/936960
53. Maev IV, Bordin DS, Eremina EU, et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Experimental and Clinical Gastroenterology. 2018;158(10):68-73 (in Russian). DOI:10.31146/1682-8658-ecg-158-10-68-73
54. Greenslade FC, Scott CK, Newquist KL, et al. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci. 1982;71(1):94-100. DOI:10.1002/jps.2600710123
55. Daly J, Bergin A, Sun WM, Read NW. Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions. Gut. 1993;34(6):799-802. DOI:10.1136/gut.34.6.799
56. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996;10(5):787-93.
DOI:10.1046/j.1365-2036.1996.61203000.x
57. Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5
DOI:10.1016/0014-2999(87)90594-2
58. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. DOI:10.3748/wjg.v16.i5.547
59. Iakovenko EP, Agafonova NA, Iakovenko AV, et al. Rol' motornykh narushenii v mekhanizmakh formirovaniia klinicheskikh proiavlenii sindroma razdrazhennogo kishechnika (SRK) i SRK-podobnykh narushenii. Voprosy terapii. Consilium medicum. 2011;1:69-73 (in Russian).
60. Lindner A, Selzer H, Claassen V, et al. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.
61. Makarchuk PA, Khalif IL, Mikhaylova TL, Golovenko OV. Changes of visceral sensitivity in patients with irritable bowel syndrome at antispasmodics treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2002;18(1):45-51 (in Russian).
62. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. DOI:10.3390/jcm11041044
63. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098-104. DOI:10.1111/j.1365-2982.2011.01771.x
64. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. DOI:10.1007/s40261-014-0233-y
65. Drozdov VN, Arefev KI, Serebrova SYu, et al. Role of antispasmodics in the treatment of irritable bowel syndrome. Meditsinskiy sovet=Medical Council. 2021;(5):155-64 (in Russian). DOI:10.21518/2079- 701X-2021-5-155-164
66. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002;29(1-2):335-40. DOI:10.1016/s0731-7085(02)00023-7
67. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8(5):499-510. DOI:10.1111/j.1365-2036.1994.tb00322.x
68. Boisson J, Coudert P, Dupuis J, et al. Tolérance de la mébévérine à long terme. Act Ther. 1987;16(4):289-92.
69. Iwase M, Nishimura Y, Kurata N, et al. Inhibitory Effects of Gastrointestinal Drugs on CYP Activities in Human Liver Microsomes. Biol Pharm Bull. 2017;40(10):1654-60. DOI:10.1248/bpb.b17-00118
70. Schiariti M, Saladini A, Placanica A, et al. QT Interval Prolongation and Atypical Proarrhythmia: Monomorphic Ventricular Tachycardia with Trimebutine. Open Pharmacol J. 2009;3:32-6. DOI:10.2174/1874143600903010032
71. Müller-Lissner SA, Kaatz V, Brandt W, et al. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroenterol Hepatol. 2005;17(1):109-12. DOI:10.1097/00042737-200501000-00020
72. Dumitrascu DL, Chira A, Bataga S, et al. Romanian Society of Neurogastroenterology. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J Gastrointestin Liver Dis. 2014;23(4):431-5. DOI:10.15403/jgld.2014.1121.234.mibs
73. Polunina TE. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Meditsinskiy sovet=Medical Council. 2020;(15):28-38 (in Russian).
DOI:10.21518/2079-701X-2020-15-28-38
74. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2(5466):848-51. DOI:10.1136/bmj.2.5466.848
75. Trukhan DI. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Spravochnik poliklinicheskogo vracha. 2012;4:32-6 (in Russian).
76. Trukhan DI. Ratsional'naia farmakoterapiia v gastroenterologii. Spravochnik poliklinicheskogo vracha. 2012;10:18-24 (in Russian).
77. Tarasova LV, Trukhan DI. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperimental'naia i klinicheskaia gastroenterologiia. 2013;4:81-7 (in Russian).
78. Trukhan DI, Tarasova LV. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klinicheskie perspektivy gastroenterologii, gepatologii. 2013;5:9-16 (in Russian).
79. Bekker RA, Bykov YuV. Eglonil®: a wonderful trinity – an atypical antipsychotic, a psychosomatic drug and an antidepressant. To the 50th anniversary of the start of its clinical use. Psychiatry and Psychopharmacotherapy. 2019;21(6):32-40 (in Russian).
Авторы
Д.И. Трухан*, В.В. Голошубина
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*dmitry_trukhan@mail.ru
Omsk State Medical University, Omsk, Russia
*dmitry_trukhan@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*dmitry_trukhan@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*dmitry_trukhan@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.